NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Astellas Pharma Inc
Eikon Therapeutics
M.D. Anderson Cancer Center
Centre Francois Baclesse
AstraZeneca
Genentech, Inc.
National Cancer Institute (NCI)
Shanghai Henlius Biotech
Gustave Roussy, Cancer Campus, Grand Paris
Eli Lilly and Company
Dana-Farber Cancer Institute
Oncolytics Biotech
New Mexico Cancer Research Alliance